Breaking Finance News

Leerink Swann upgraded Celgene Corporation (NASDAQ:CELG) to Outperform in a report released today.

Leerink Swann has upgraded Celgene Corporation (NASDAQ:CELG) to Outperform in a report released on Friday June 16, 2017.

Just yesterday Celgene Corporation (NASDAQ:CELG) traded 0.08% higher at $120.61. Celgene Corporation’s 50-day moving average is $135.45 and its 200-day moving average is $127.81. The last stock price is down 12.59% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 3,549,466 shares of Celgene Corporation exchanged hands, down from an avg. volume of 3,733,020

Performance Chart

Celgene Corporation (NASDAQ:CELG)

With a total market value of $0, Celgene Corporation has price-earnings ratio of 44.56 with a one year low of $96.93 and a one year high of $144.19 .

A total of 22 equity analysts have released a research note on CELG. Ten equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, four equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $136.82.

More About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.